Key Strategies Adopted by Leading Players to Enhance Growth in the Global Tumor Ablation Market

PUNE, India, 2020-Aug-05 — /EPR Network/ —

The global tumor ablation market is expected to reach USD 580.1 million by 2021, at CAGR of 12.5% from 2016 to 2021. Key factors such growing geriatric population, continuous expansion in population base of cancer patients across the globe, and ongoing technological advancements in the field of tumor ablation product are the major factors driving the growth of the tumor ablation market across the globe.

The key players present in the global tumor ablation market focus on various strategies such as product approvals, launches, and enhancements; strategic acquisitions; partnerships, agreements, and collaborations; and geographic expansions in order to increase their shares in the global tumor ablation market. During 2013-2016, product approvals, launches, and enhancements; and acquisitions were the key strategies adopted by major industry players, including AngioDynamics, Inc. (U.S.), Boston Scientific Corporation (U.S.), Galil Medical (Israel), EDAP TMS S.A. (France), HealthTronics, Inc. (U.S.), Medtronic plc (Ireland), and SonaCare Medical LLC (U.S.). Other strategies adopted by many prominent players include fund raising from private/government sources to enhance their research & development capabilities; initiatives to increase awareness about tumor ablation; and geographic expansions.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=142550258

As of 2015, Medtronic plc (Ireland) held the leading position in the tumor ablation market owing to its robust product portfolio and its strong geographic presence across major markets (such as the U.S., Europe, China, Japan, Brazil, and India). The company primarily focuses on strategic acquisitions and development of technologically advanced tumor ablation systems as its key growth strategies to sustain its leadership position in the market.

In line with this strategy, during 2013-2016, the company launched several tumor ablation products such as OsteoCool RF Ablation System (2016) and Barrx 360 Express radiofrequency ablation (RFA) balloon catheter (2016). The company also adopted geographic expansion as another key growth strategy to strengthen its sales and product distribution capabilities. In line with this, Medtronic set up the Asia-Pacific regional headquarters in Singapore Singapore Health Services (SingHealth) in May 2016; SingHealth will help streamline and expand the company’s regional operations across 80 locations in Asia-Pacific.

AngioDynamics, Inc. (U.S.) held the second position in the tumor ablation market in 2015. The company has a strong product portfolio in the global tumor ablation market, including products such as Acculis MTA system, NanoKnife system, StarBurst RFA system, and UniBlate RFA electrodes. The company pursued strategic acquisitions and expansions of existing product portfolio (as well as pipeline development) as its key growth strategies.

During 2013-2016, AngioDynamics acquired Microsulis Medical Ltd. (U.S.) and Navilyst Medical Inc. (U.S.); these acquisitions helped the company strengthen its market position and geographic presence. Additionally, in August 2016, AngioDynamics reported excellent clinical results with its Acculis Microwave Tissue Ablation System during cancer treatment studies (lung tumor, bone tumor, and renal tumor). This helped company to further strengthen the pipeline development for microwave ablation products.

North America is expected to dominate the market in 2016

As of 2016, North America held the largest share of the global tumor ablation market, followed by Europe. The large share of North America in the global tumor ablation market can be attributed to the early introduction and high adoption rate of tumor ablation products in the region, significant trend of replacing older technologies with advanced and innovative therapeutic techniques (such as microwave and cryoablation), and increasing private/public funding to develop and commercialize novel tumor ablation products.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=142550258

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com